Tartrate-resistant acid phosphatase 5b is a potential biomarker for rheumatoid arthritis: a pilot study in Han Chinese |
| |
Authors: | Cheng Tao Wang Mingjun Chen Zhiwei Robert A Eisenberg Zhang Yu Zou Yaohong Deng Yingsu Wang Mian and Zhou Ling |
| |
Institution: | [1]Department of Rheumatology , First AffiliatedHospital of Soochow University, Suzhou, Jiangsu 215000, China; [2]Department of Nephrology , First AffiliatedHospital of Soochow University, Suzhou, Jiangsu 215000, China; [3]Department of Rheumatology, University of Pennsylvania, Philadelphia 19104, USA; [4]Department of Hematology, Subei People's Hospital, Yangzhou,Jiangsu 225001, China; [5]Department of Rheumatology, Wuxi First People's Hospital, Wuxi,Jiangsu 214043, China; [6]School of Public HealS, Central South University, Changsha, Hunan 410083, China |
| |
Abstract: | Background Bone damage around the joints is one of the major pathophysiological mechanisms that leads to rheumatoid arthritis (RA) chronic disability. Serum tartrate-resistant acid phosphatase 5b (TRACP-5b) is secreted by osteoclasts, its activity can be used as a clinically relevant bone resorption marker. The aim of this study was to test whether the measurement of serum levels of TRACP-5b in patients with RA would correlate with measures of disease activity and with responses to therapy. Methods Fifty-six patients were randomly assigned to receive recombinant human cytotoxic tlymphocyte-associated antigen-4 immunoglobulin (RhCTLA4-Ig), infliximab or methotrexate (MTX). The clinical and serologic indicators of RA activity were evaluated at baseline and at 24 weeks. Serum TRACP-5b was measured by Enzyme-linked Immunosorbent Assay (ELISA) at 0, 12 and 24 weeks. Hand X-rays were obtained at baseline. Results At baseline, the levels of TRACP-5b correlated with the severity of X-ray damage, disease duration (r=0.332, P=0.012), and tender joint count (r=0.408, P=0.002). The 24 weeks values of TRACP-5b for RhCTLA4-Ig group and infliximab group differed significantly from the baseline values in each group (P <0.05; P <0.05), whereas only the value for RhCTLA4-Ig group differed significantly from the 24 weeks value for the MTX group (P <0.01). Considering the two biologics-treated groups together, the TRACP-5b levels at 24 weeks differed significantly from the baseline values only in those patients who reached an ACR70 level (P <0.05). Conclusions Measurement of serum TRACP-5b in RA patients reflects clinical and radiological measures of disease activity, treatment with certain biologics, and degree of response to therapy. TRACP-5b should be investigated further as a potential biomarker to predict response to therapy, including slowing of radiographic progression. |
| |
Keywords: | tartrate-resistant acid phosphatase 5b rheumatoid arthritis Chinese osteoclast biologic agent |
本文献已被 维普 等数据库收录! |
| 点击此处可从《中华医学杂志(英文版)》浏览原始摘要信息 |
| 点击此处可从《中华医学杂志(英文版)》下载免费的PDF全文 |
|